company background image
HRMY logo

Harmony Biosciences Holdings NasdaqGM:HRMY Stock Report

Last Price

US$33.00

Market Cap

US$1.9b

7D

-2.6%

1Y

-28.7%

Updated

21 Feb, 2024

Data

Company Financials +

Harmony Biosciences Holdings, Inc.

NasdaqGM:HRMY Stock Report

Market Cap: US$1.9b

HRMY Stock Overview

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

HRMY fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Harmony Biosciences Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Harmony Biosciences Holdings
Historical stock prices
Current Share PriceUS$33.00
52 Week HighUS$46.97
52 Week LowUS$18.61
Beta0.73
1 Month Change1.44%
3 Month Change15.79%
1 Year Change-28.68%
3 Year Change-11.17%
5 Year Changen/a
Change since IPO-10.83%

Recent News & Updates

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Feb 09
Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Recent updates

Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Feb 09
Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings

Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Mar 21
Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Dec 01
Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?

Harmony Biosciences: In Harmony

Sep 23

We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Aug 05
We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease

Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M

Aug 02

Harmony Biosciences: Steady Revenue Generator Looking For A Future

May 26

Harmony Biosciences: Strong Growth At A Reasonable Price

Mar 04

Our First Look At Harmony Biosciences

Nov 04

Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations

Aug 17
Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations

Harmony Biosciences Is Likely To Trade Higher As Wakix Sales Build

Jul 13

Harmony Bio reports clinical impact of Wakix in excessive daytime sleepiness at SLEEP 2021

Jun 10

Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 14
Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shareholder Returns

HRMYUS PharmaceuticalsUS Market
7D-2.6%0.7%-0.5%
1Y-28.7%20.6%22.5%

Return vs Industry: HRMY underperformed the US Pharmaceuticals industry which returned 20.2% over the past year.

Return vs Market: HRMY underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is HRMY's price volatile compared to industry and market?
HRMY volatility
HRMY Average Weekly Movement5.7%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.0%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: HRMY's share price has been volatile over the past 3 months.

Volatility Over Time: HRMY's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017200Jeffrey Daynohttps://www.harmonybiosciences.com

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.

Harmony Biosciences Holdings, Inc. Fundamentals Summary

How do Harmony Biosciences Holdings's earnings and revenue compare to its market cap?
HRMY fundamental statistics
Market capUS$1.93b
Earnings (TTM)US$150.76m
Revenue (TTM)US$541.92m

12.8x

P/E Ratio

3.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HRMY income statement (TTM)
RevenueUS$541.92m
Cost of RevenueUS$104.97m
Gross ProfitUS$436.95m
Other ExpensesUS$286.19m
EarningsUS$150.76m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 22, 2024

Earnings per share (EPS)2.57
Gross Margin80.63%
Net Profit Margin27.82%
Debt/Equity Ratio41.0%

How did HRMY perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.